By Nana O 
Researchers from the Montefiore Einstein Comprehensive Cancer Center (MECCC) and the Albert Einstein College of Medicine have unveiled a groundbreaking discovery about glioblastoma, the most aggressive and lethal form of brain cancer. Far from being a localized threat to brain tissue, this formidable disease actively engages in a destructive dialogue with the skull and the body’s immune system, fundamentally altering bone marrow composition and immune cell dynamics. The implications of these findings, published on October 3 in the prestigious journal Nature Neuroscience, are profound, suggesting a paradigm shift in understanding and treating this devastating illness. Crucially, the research indicates that medications designed to combat bone loss, paradoxically, may exacerbate glioblastoma’s aggression.
"Our discovery that this notoriously hard-to-treat brain cancer interacts with the body’s immune system may help explain why current therapies — all of them dealing with glioblastoma as a local disease — have failed, and it will hopefully lead to better treatment strategies," stated Dr. Jinan Behnan, the paper’s corresponding author. Dr. Behnan, an assistant professor in the Leo M. Davidoff Department of Neurological Surgery and the Department of Microbiology & Immunology at Einstein, and a distinguished member of the National Cancer Institute (NCI)-designated MECCC, underscored the significance of this systemic perspective.
Glioblastoma presents a stark reality for patients. The National Cancer Institute (NCI) estimates that approximately 15,000 individuals in the United States are diagnosed with glioblastoma annually. Despite aggressive treatment regimens, which typically involve a combination of surgery, chemotherapy, and radiation, the median survival time remains tragically short, hovering around 15 months. This limited efficacy has long spurred the scientific community to seek a deeper understanding of the tumor’s complex biology.
A Matter of Marrow: The Skull’s Hidden Role
The skull, often perceived as a protective casing for the brain, is a dynamic organ containing bone marrow. This marrow is a crucial hematopoietic factory, responsible for producing essential immune cells and other blood components. Dr. Behnan’s team was initially inspired by emerging research highlighting the existence of intricate, ultra-thin channels that connect the skull to the brain. These channels, previously underestimated, are now understood to facilitate the vital exchange of molecules and immune cells between these two distinct but interconnected compartments.
Leveraging cutting-edge imaging technologies, the researchers meticulously examined mice engineered to develop two distinct types of glioblastoma. Their observations revealed a disturbing pattern: the cancer actively induced erosion of the skull bones, with a particular predilection for the sutures, the fibrous joints where cranial bones fuse. This phenomenon of bone loss was found to be highly specific to glioblastoma and other aggressive brain tumors. In stark contrast, mice experiencing strokes, other forms of brain injury, or cancers located elsewhere in the body did not exhibit this calvarial erosion. Further validating their findings in human patients, CT scans of individuals diagnosed with glioblastoma displayed a comparable reduction in skull thickness in the same anatomical regions identified in the mouse models.
The study’s analysis indicated that the glioblastoma-induced erosion of skull bone led to an expansion in both the number and size of the channels linking the skull and the brain. The scientific hypothesis posited by the researchers is that these augmented channels serve as conduits, enabling the tumor to transmit molecular signals into the skull marrow. This influx of tumor-derived signals, they proposed, could then profoundly alter the immune microenvironment within the marrow itself.
A Tilt Toward Inflammation: Immune System Hijacked
Employing sophisticated single-cell RNA sequencing techniques, the researchers delved into the immunological consequences of glioblastoma’s assault on skull marrow. Their findings were stark: the cancer had dramatically reshaped the immune-cell landscape within the skull marrow, decisively tipping the balance in favor of pro-inflammatory myeloid cells. Specifically, the study observed a near doubling of inflammatory neutrophils, a type of white blood cell crucial for combating infection but also implicated in inflammatory responses. Concurrently, several types of antibody-producing B cells, as well as other B cell populations vital for adaptive immunity, were nearly eradicated.
"The skull-to-brain channels allow an influx of these numerous pro-inflammatory cells from the skull marrow to the tumor, rendering the glioblastoma increasingly aggressive and, all too often, untreatable," explained Dr. E. Richard Stanley, a co-author of the study and a professor of Developmental and Molecular Biology at Einstein. "This indicates the need for treatments that restore the normal balance of immune cells in the skull marrow of people with glioblastoma. One strategy would be suppressing the production of pro-inflammatory neutrophils and monocytes while at the same time restoring the production of T and B cells."
Adding further weight to the notion that glioblastoma operates as a systemic disease rather than a purely localized one, the research revealed differential responses between the skull marrow and the femur marrow. Glioblastoma actively stimulated the expression of several genes within the skull marrow, thereby promoting the production of inflammatory immune cells. In contrast, within the femur marrow, the cancer acted to suppress genes essential for the generation of various types of immune cells. This dichotomy underscores the multifaceted and far-reaching impact of glioblastoma on the body’s hematopoietic and immune systems.
Paradoxical Interventions: Bone Health Drugs and Cancer Progression
The researchers’ curiosity extended to the potential impact of anti-osteoporosis medications, drugs designed to prevent bone loss, on glioblastoma’s trajectory. They hypothesized that these drugs might influence skull-bone erosion, glioblastoma progression, or both. To test this, they administered two FDA-approved osteoporosis medications, zoledronic acid and denosumab, to mice bearing glioblastoma tumors.
The results were illuminating and, in some respects, concerning. Both zoledronic acid and denosumab effectively halted skull erosion. However, one of these drugs, zoledronic acid, demonstrated a detrimental effect by fueling tumor progression in one specific type of glioblastoma model. Furthermore, both drugs exhibited an inhibitory effect on the efficacy of anti-PD-L1, a promising immunotherapy drug that works by enhancing the activity of tumor-fighting T cells. This finding suggests a complex interplay where interventions aimed at one aspect of the disease could inadvertently compromise the effectiveness of other therapeutic strategies.
Broader Implications and Future Directions
The findings of this study have far-reaching implications for the future of glioblastoma research and treatment. The established understanding of glioblastoma as a purely intracranial malignancy has long dictated therapeutic approaches. This new research challenges that paradigm, demonstrating that the tumor actively manipulates the systemic environment, particularly the skull’s bone marrow, to its advantage.
The identification of enlarged skull-to-brain channels as a potential pathway for pro-inflammatory cells to reach the tumor offers a tangible target for novel therapeutic interventions. Restoring the balance of immune cells within the skull marrow, by modulating the production of neutrophils and monocytes while concurrently bolstering T and B cell populations, emerges as a promising avenue for future drug development.
The paradoxical interaction with bone-modifying agents also highlights the critical need for comprehensive pre-clinical testing of any therapeutic strategy in the context of glioblastoma’s systemic effects. The discovery that drugs designed to protect bone could potentially accelerate tumor growth underscores the intricate and often counterintuitive biological processes at play.
The paper, titled "Brain Tumors Induce Widespread Disruption of Calvarial Bone and Alteration of Skull Marrow Immune Landscape," is the culmination of collaborative efforts involving numerous researchers from MECCC and Einstein, including Abhishek Dubey, Biljana Stangeland, Imane Abbas, David Fooksman, Ph.D., Wade R. Koba, B.S., Jinghang Zhang, M.D., Benjamin T. Himes, Ph.D., Derek Huffman, Ph.D., Zhiping Wu, Rachel Welch, David Reynolds, B.S., Kostantin Dobrenis, Ph.D., Qinge Ye, Kevin Fisher, and Emad Eskandar, M.D. International contributions were also made by Erika Yamashita, Yutaka Uchida, and Masaru Ishii from Osaka University, Japan; Robert A. Harris from Karolinska Hospital, Sweden; Gregory M. Palmer from Duke University Medical Center, USA; Olivia R. Lu and Winson S. Ho from the University of California, San Francisco, USA; and Alexander F. Fiedler from the German Rheumatism Research Center (DRFZ) and Freie Universität Berlin, Germany.
This extensive collaboration signifies the global scientific community’s commitment to unraveling the complexities of glioblastoma. The insights gained from this research pave the way for a more holistic approach to understanding and combating this devastating disease, offering a glimmer of hope for improved treatment strategies and, ultimately, better outcomes for patients. The focus is now shifting towards developing therapies that target the tumor’s systemic influence, rather than solely its local presence, a crucial step in the ongoing battle against glioblastoma.
